<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent insight into the pathogenesis of <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD) and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) have led to the development of new treatment options, with a progressive shift to more evidence-based strategies based on sound pathophysiological rationales </plain></SENT>
<SENT sid="1" pm="."><plain>A better understanding of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) pathophysiology has progressively resulted in a more frequent use of immunomodulators </plain></SENT>
<SENT sid="2" pm="."><plain>We review the recommended or suggested use of conventional immunomodulators such as <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, <z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> in the treatment of IBD </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, an effort is made to explore some critical areas in which early and more diffuse use of these agents may be advocated </plain></SENT>
</text></document>